Get the Weekly Intelligence Brief — top committee picks every Sunday.

ALC vs SNY

Alcon Inc vs Sanofi — AI-powered side-by-side comparison
ALC
Alcon Inc
68
Buy
VS
SNY
Sanofi
62
Insufficient Data
MetricALCSNY
AI Score 68 62
Price $75.39 $43.56
P/E Ratio 45.39× 23.06×
ROE 4.4% 10.9%
Revenue Growth YoY
Gross Margin 54.9% 72.8%
Debt / Equity 0.24× 0.34×
Dividend Yield 0.5% 5.5%
RSI (14) 73.4 53.1
Beta 0.703 0.278
Expected Upside +11.3%

AI Committee View

Current Innellis committee reasoning for ALC versus SNY.
ALC leads by 6 points.

ALC scores 68/100 (Buy) versus SNY at 62/100 (Insufficient Data).

ALC Committee View
75% agreement
4 analysts

The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.

Bull Case
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
  • RSI at 73 is in overbought territory — Technical
  • Price trading above the upper Bollinger Band -- stretched — Technical
SNY Committee View
67% agreement
3 analysts

Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.

Bull Case
  • Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • Price structure making lower highs and lower lows — Technical
  • MACD histogram negative -- bearish momentum — Technical
  • Trend and market structure agree -- coherent bearish picture — Technical
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
ALC Full Analysis SNY Full Analysis